CD274 and colorectal carcinoma: These results are consistent with the hypothesis that inhibition of the PD-1/PD-L1 immune check point mitigates 5-FU/oxaliplatin-induced upregulation of PD-L1, ultimately enhancing chemotherapy efficacy in this mouse model of CRC.